BioWa Revenue and Competitors
Estimated Revenue & Valuation
- BioWa's estimated annual revenue is currently $1.7M per year.
- BioWa's estimated revenue per employee is $155,000
Employee Data
- BioWa has 11 Employees.
- BioWa grew their employee count by -8% last year.
BioWa's People
| Name | Title | Email/Phone |
|---|
BioWa Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $10.1M | 65 | 5% | N/A | N/A |
#10 | $16.1M | 104 | 9% | N/A | N/A |
What Is BioWa?
BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin. BioWa is the exclusive worldwide licensor of Potelligent® Technology, a proprietary technology that creates 100% fucose-free monoclonal antibodies – antibodies that demonstrate a marked increase in antibody-dependent cellular cytotoxicity (ADCC). A critical function of the immune system, ADCC enhances the ability of antibodies to kill tumor cells. With BioWa’s technology, enhancement of monoclonal antibody (Mab) potency has been shown to increase up to 100 fold both in vitro and in vivo.
keywords:N/A
N/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1M | 11 | 0% | N/A |
#2 | $0.4M | 11 | 0% | $21.5M |
#3 | $1M | 11 | 0% | N/A |
#4 | $1M | 11 | N/A | N/A |
#5 | $1M | 11 | N/A | N/A |